Straits Times Index
3,328.41 -1.68 (-0.05%) S&P 500
5,306.04 +1.32 (+0.02%) Dow
38,852.86 -216.74 (-0.55%) Nasdaq
17,019.88 +99.08 (+0.59%) Bitcoin USD
67,782.01 -293.70 (-0.43%) CMC Crypto 200
1,460.09 -24.61 (-1.66%)
Ventyx Biosciences, Inc. (VTYX)
After hours:
| Previous close | 4.37 |
| Open | 4.44 |
| Bid | 5.11 x 100 |
| Ask | 5.14 x 200 |
| Day's range | 4.41 - 5.22 |
| 52-week range | 1.87 - 40.58 |
| Volume | |
| Avg. volume | 1,538,501 |
| Market cap | 361.661M |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.80 |
| Earnings date | 25 Mar 2024 - 29 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.70 |
GlobeNewswireVentyx Biosciences to Participate in Three Upcoming Investor Conferences
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences: Event: UBS Obesity Therapeutics DayLocation: VirtualDate: Thursday, May 23, 2024Time: 12:00-12:30 PM ET Event: Jefferies Glob
- GlobeNewswire
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer. “I am excited to welcome Matt to the Ventyx leadership team,” said Raju Mohan, Chief Executive Officer. “He brings a wealth of expertise to V
Insider MonkeyVentyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q1 2024 Earnings Call Transcript May 11, 2024 Ventyx Biosciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, ladies and gentlemen and welcome to the Ventyx Biosciences First Quarter 2024 Earnings Conference Call. […]
